Comparison of the efficacy of esomeprazole 40mg and fexuprazan 40mg for symptom control of nocturnal acid breakthrough in gastroesophageal reflux disease

Dongguk University Ilsan Hospital0 个研究点目标入组 40 人开始时间: 待定最近更新: 2023年6月26日

适应症

试验速览

暂无简介。

•1) Adults between the ages of 19 and 80
•2) Patients with erosive reflux esophagitis confirmed by gastroscopy
•3) Patients who have repeatedly had nocturnal acid secretion symptoms within the previous 3 months
•4) Patients who have improved symptoms with PPI or gastric acid secretion inhibitor
•5) Those who can understand and follow instructions and participate in the clinical trial

•1) Those with swallowing disorder or diagnosed with esophageal motility disease
•2) Those who have been diagnosed with peptic ulcer and gastric cancer by gastroscopy within 3 months
•3) Patients with gastroesophageal reflux disease who are refractory to PPI treatment
•4) Patients who have undergone previous total gastrectomy
•5) Patients who have participated in other clinical trials within 30 days from the date of screening and are taking investigational drugs
•6) Those who fall under the contraindications in the precautions for use of investigational drugs
•7) Patients who are pregnant or plan to become pregnant
•8) Others judged by the researcher to be unfit to participate in this test

发起方